Bcworldpharm비씨월드제약

Bcworldpharm returned to a small operating profit on higher trailing revenue, but it still posted a net loss and the shares are down sharply over the past year.

Trailing twelve-month revenue to H1 2026 was about ₩80.3B with operating income of ₩2.8B (3.5% margin), while net income was a loss of ₩2.9B. The stock closed at ₩2,940 on 2026-10-19, roughly 38% below its one-year level, with a market cap of about ₩31.4B. The data shows a company with modest operations, net losses in recent years and a balance sheet with liabilities at 143% of equity.

What stands out

• Trailing operating margin of 3.5% is up from 2.6% in 2025 and 2.0% in 2024, but net income remains negative at -₩2.9B on a TTM basis.
• 2025 net loss of ₩4.9B was larger than the 2024 loss of ₩4.4B, even though operating income rose to ₩2.0B.
• Cash of about ₩3.9B and positive trailing free cash flow of ₩4.7B are shown, but the data shows no borrowings figure.
• Valuation metrics are low: price-to-book 0.5, EV/EBITDA 2.6, dividend yield 3.4%, with no meaningful P/E because earnings are negative.
• The discounted cash flow model gives a base value of ₩12,387 against the ₩2,940 close, with a bear case of ₩7,767 and a bull case of ₩20,011. These are model outputs, not forecasts.

What to watch

• The corporate value-up plan filed on 2026-10-19 (and an earlier one on 2026-03-26); the data does not include its contents.
• Full-year 2026 results, since the data only covers trailing figures to H1 2026 and the net loss has persisted.
• Continued 5%+ holding reports and insider share filings; foreign ownership is only 1.3%, and the data includes no recent news headlines.